Effect of PCSK9 inhibition with evolocumab on lipoprotein subfractions in familial dysbetalipoproteinemia (type III hyperlipidemia).
<h4>Background and aims</h4>Familial dysbetalipoproteinemia (FDBL) is a rare inborn lipid disorder characterized by the formation of abnormal triglyceride- and cholesterol-rich lipoproteins (remnant particles). Patients with FDBL have a high risk for atherosclerotic disease. The effect o...
Main Authors: | Elisa Waldmann, Liya Wu, Kristina Busygina, Julia Altenhofer, Kerstin Henze, Alexander Folwaczny, Klaus G Parhofer |
---|---|
Format: | Article |
Language: | English |
Published: |
Public Library of Science (PLoS)
2022-01-01
|
Series: | PLoS ONE |
Online Access: | https://doi.org/10.1371/journal.pone.0265838 |
Similar Items
-
Effect of PCSK9 inhibition with evolocumab on lipoprotein subfractions in familial dysbetalipoproteinemia (type III hyperlipidemia)
by: Elisa Waldmann, et al.
Published: (2022-01-01) -
Postprandial Lipid Metabolism in Normolipidemic Subjects and Patients with Mild to Moderate Hypertriglyceridemia: Effects of Test Meals Containing Saturated Fatty Acids, Mono-Unsaturated Fatty Acids, or Medium-Chain Fatty Acids
by: Alexander Folwaczny, et al.
Published: (2021-05-01) -
Efficacy and safety of the PCSK9 inhibitor evolocumab in patients with mixed hyperlipidemia
by: Preiss, D, et al.
Published: (2016) -
Effect of Evolocumab on Lipoprotein(a) and PCSK9 in Healthy Individuals with Elevated Lipoprotein(a) Level
by: Olga Afanasieva, et al.
Published: (2020-10-01) -
FAMILIAL DYSBETALIPOPROTEINEMIA (TYPE III HYPERLIPOPROTEINEMIA)
by: P. P. Malyshev, et al.
Published: (2019-03-01)